Simultaneous Spectrophotometric Method for Determination of Emtricitabine and Tenofovir Disoproxil Fumarate in Three-Component Tablet Formulation Containing Rilpivirine Hydrochloride

Table 6

Ruggedness results for EMT, TDF, and RPV.

Parameter	EMT			TDF			RPV
	Amount present			Amount present			Amount present
	(gm)	(%)	%RSD	(gm)	(%)	%RSD	(gm)	(%)	%RSD
Analyst 1	0.1995	99.79	0.65	0.2985	99.50	0.95	0.0251	100.47	0.74
Analyst 2	0.2001	100.05	1.03	0.2996	99.86	1.28	0.0250	100.25	0.98
Instrument 1	0.1999	99.67	0.68	0.2981	99.38	0.79	0.0248	99.33	0.84
Instrument 2	0.2000	100.04	0.85	0.2989	99.65	0.81	0.0251	100.58	0.89
Lab1	0.2004	100.20	0.59	0.3000	100.0	0.58	0.0253	101.24	0.84
Lab 2	0.1999	99.97	0.54	0.2977	99.26	0.84	0.0248	99.38	0.83